Exposure-Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First-Line Therapy for Locally Advanced or Metastatic Urothelial Cancer.

Padcev (enfortumab vedotin-ejfv) - Astellas, Pfizer

Keytruda (pembrolizumab) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/42717277

Amit Garg; Daping Zhang; Helen Kastrissios; Hossam Kadry; Russ Wada; Salaheldin Hamed; Souvik Bhattacharya; Srinivasu Poondru; Vaishali L Chudasama; Yen Lin Chia

Sep 11, 2026